Another compound targeting the KRAS G12C variant, ARS-853, selectively reduced the frequency of the active, GTP-bound KRAS, and inhibited cell proliferation in lung cancer models and suggests that nucleotide cycling between GDP and GTP bound forms are essential for its molecular functions (94, 95). The gene discussed is KRAS; the disease is lung carcinoma.